×
Use Able AI chat for product recommendations

Recombinant Mouse IGFBP6 protein (rFc Tag)

Species

Mouse

Purity

>90 %, SDS-PAGE

Tag

rFc Tag

Activity

not tested

Cat no : Eg10273

Validation Data Gallery

  • Purity of Recombinant Mouse IGFBP6 was determined by SDS-PAGE. The protein was resolved in an SDS-PAGE in reducing (R) and non-reducing (NR) conditions and stained using Coomassie blue.

    Purity of Recombinant Mouse IGFBP6 was determined by SDS-PAGE. The protein was resolved in an SDS-PAGE in reducing (R) and non-reducing (NR) conditions and stained using Coomassie blue.

Product Information

Purity >90 %, SDS-PAGE
Endotoxin <0.1 EU/μg protein, LAL method
Activity 
Not tested
Expression HEK293-derived Mouse IGFBP6 protein Ala26-Gly238 (Accession# P47880) with a rabbit IgG Fc tag at the C-terminus.
GeneID 16012
Accession P47880
PredictedSize 48.3 kDa
SDS-PAGE 48-60 kDa, reducing (R) conditions
Formulation Lyophilized from 0.22 μm filtered solution in PBS, pH 7.4. Normally 5% trehalose and 5% mannitol are added as protectants before lyophilization.
Reconstitution Briefly centrifuge the tube before opening. Reconstitute at 0.1-0.5 mg/mL in sterile water.
Storage Conditions
It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
  • Until expiry date, -20℃ to -80℃ as lyophilized proteins.
  • 3 months, -20℃ to -80℃ under sterile conditions after reconstitution.
Shipping The product is shipped at ambient temperature. Upon receipt, store it immediately at the recommended temperature.

Background

Insulin-like growth factor-binding protein 6 (IGFBP6) is a secreted protein with a uniquely high affinity for IGF-II, distinguishing it within the IGFBP family. Beyond its canonical role as an IGF-II antagonist, IGFBP6 possesses diverse IGF-independent functions, including the activation of MAPK and PI3K/Akt pathways to influence cell migration, survival, and metabolism. It can translocate to the nucleus to induce apoptosis and its activity is modulated by proteolytic cleavage via MMPs. Pathologically, IGFBP6 is a context-dependent regulator: it acts as a tumor suppressor in breast cancer (favorable prognosis), an anti-inflammatory factor in atherosclerosis, a driver of cardiac and hepatic fibrosis, an orchestrator of immune collapse in sepsis, and a predictor of reduced type 2 diabetes risk. Thus, IGFBP6 is a pleiotropic target with dual diagnostic and therapeutic potential across oncology, inflammation, metabolism, and cardiovascular disease.

References:

1.Schwartz, Martin A. Nature cardiovascular research vol. 4,2 (2025): 122-123. 
2.Wang, Zhecun et al. Journal of cellular physiology vol. 235,12 (2020): 9538-9556. 
3.Jin, Zhengxin et al. Communications biology vol. 8,1 1127. 29 Jul. 2025,
||
New chat

Able™

正在加载，请稍候...